CCL2 and lupus nephritis: Further analysis of inflammatory markers revealed that SAP treatment notably decreased systemic and local inflammatory cytokine levels of TNF-α, IL-1β, IL-6, IL-12, and MCP-1, which were closely associated with the severity of lupus nephritis [18].